Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | JAK1 | P23458 | 1/20 | 0.62 |
| ▸ | BRD2 | P25440 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.62 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221583 | 0.88 | BRD4 (1.00) | BRD4JAK1BRD2JAK3BRD3 | |
| SCHEMBL30306500 | 0.88 | BRD4 (0.78) | BRD4JAK1BRD2JAK3BRD3 | |
| SCHEMBL18757719 | 0.87 | BRD4 (0.85) | BRD4JAK1BRD2JAK3BRD3 | |
| SCHEMBL18757687 | 0.86 | BRD4 (1.00) | BRD4JAK1BRD2JAK3BRD3 | |
| SCHEMBL1906361 | 0.86 | BRD4 (0.77) | BRD4EGFRJAK1BRD2JAK3 | |
| SCHEMBL270740 | 0.86 | BRD4 (0.69) | BRD4EGFRJAK1BRD2JAK3 | |
| Hydrochloric Acid SCHEMBL264399 | 0.85 | BRD4 (0.68) | BRD4EGFRJAK1BRD2JAK3 | |
| SCHEMBL17526072 | 0.83 | BRD4 (1.00) | BRD4JAK1BRD2JAK3BRD3 | |
| SCHEMBL30306540 | 0.83 | BRD4 (0.73) | BRD4EGFRBRD2BRD3BRDT | |
| SCHEMBL1607993 | 0.79 | BRD4 (0.63) | BRD4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | BRD4 1/4885EGFR 452/4885JAK1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.